ПОЛ Родерик (US),ХАУЗЕР Роберт (US),ЛИ Мин (US),УИЛСОН Брайан Р. (US)
申请号：
RU2014145846
公开号：
RU2014145846A
申请日:
2013.04.16
申请国别(地区):
RU
年份:
2016
代理人:
摘要：
1. A pharmaceutically acceptable injectable formulation comprising: insulin effective amount of a first compound which chelating zinc insulin hexamers to dissociate to monomers and dimers of insulin, the effective amount of a second compound that stabilizes the resulting dissociation monomers and dimers of insulin ieffektivnoe amount of one or more magnesium compounds to reduce discomfort at the injection site, compared to the discomfort at the site of injection, the dosage form in the absence of one or more compounds magniya.2. Composition according to Claim. 1, wherein the insulin is human recombinant insulin.3. Composition according to Claim. 1, wherein the insulin is an analogue insulina.4. Composition according to Claim. 1, wherein the insulin concentration was 100, 200, 400 or 500 IU / ml.5. Composition according to Claim. 1 or 2, wherein the one or more magnesium compounds are selected from the group consisting of inorganic magnesium salts, organic magnesium salts and kombinatsiy.6. Composition according to claim. 4, wherein the inorganic magnesium salts are selected from the group consisting of magnesium hydroxide (Mg (OH)), magnesium sulfate (Mg (SO)), magnesium halides such as magnesium chloride (MgCl), magnesium bromide (MgBr ) and magnesium iodide (MgI) magnesium pyrophosphate, magnesium sulfate heptahydrate, magnesium oxide (MgO) and kombinatsiy.7. . The composition according to claim 4, wherein the organic magnesium salts are selected from the group consisting of EDTA magnesium salt, magnesium lactate, amino acid chelated compounds such as magnesium aspartate magnesium acetate, magnesium carbonate (Mg (CO)), magnesium citrate and gluconate magniya.8. Composition according to any one of claims. 1-6, wherein one ilineskolko magnesium compounds are Mg (OH), MgSO, EDTA magnesium salt or kombinatsii.9. Composition according to any one of claims. 1-7, in which1. Фармацевтически приемлемый инъецируемый состав, содержащий:инсулинэффективное количество первого
